Cluster members solved the problem of lacking lab infra by innovating and developing new, simple, cost effective and environment friendly solutions and products
Utilizing and further developing existing successful technologies (dominantly in development, manufacturing, and sales of immunodiagnostics, lab devices and equipment) and introducing new ones (genetic, genomic, in vitro and in vivo new trial models, products and services) the cluster members developed new products and services especially designed for the diagnostic infrastructure and activity of smaller formal and informal healthcare providers and business/industry actors. The accredited innovation cluster management – in partnership with and assisted by the R+D, education and techtransfer activities of the University of Pécs - provided its technology incubation background, and the cluster members shared their experiences in innovation, product and production design and marketing. The cluster is managed by a limited company owned by the Municipality of Pécs. Cluster members solved lacking laboratory infrastructure by innovating and developing new, cost effective and environment friendly solutions and products. Appropriate lab infrastructure for efficient and effective diagnosis and participation in clinical trials was developed. The infra opened access for SMEs to save time & costs to test new reagents or molecules for new drugs and medicines or devices, and gave support to functional or personalized medicine. In 2009 MA of EDOP approved the cluster’s application submitted to the call “Supporting joint technological innovation of accredited innovation clusters”.
The overall budget of the project amounted HUF 574 430 000 (app. EUR 2.0 M).
Rate of support gained from the OP: 50%.
Evidence of success
The project delivered immunodiagnostic solution to develop, manufacture and sale in vitro diagnostic (IVD) medical devices, equipment, reagents and services for quick, reliable and cost effective diagnosis for patients and the physicians outside the big clinical environment. It had positive impact on access to lab infra for 8 cluster members. The project itself did not targeted home care, however, better diagnosis helps to develop innovative medicines for personalised/functional care.
Sustainability of operation after the closure of the maintenance period of the ESIF projects shall be solved, e.g. relevant groups such as health care insurance (fund/companies), health technology assessment organizations or other stakeholder groups should be involved.
Potential for learning or transfer
Grants and any other resources invested in innovation are used in a more effective and efficient way if the market accepts it quickly. The end users’ market needs services instead of pure products, therefore, it’s important to realize that service oriented innovation (either executed in quadruple helix cooperation or in clusters of less stakeholders) should be supported.
The innovation in the service of health care providers (e.g. new treatment procedures) and the technological development shall be integrated in the same project/programme and supported in coordinated way or in the same grant scheme.
Cooperation among cluster members, management and university helped to define real unmet needs and markets, which paved the way for innovation by using and further developing existing knowledge and technologies. The whole process was catalyzed by the system of accrediting innovation clusters and supporting the joint technological innovation of cluster members.